Systematic review, meta-analysis and economic modelling of ...

More documents

Recommendations

Info

References83. Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I measured bythe high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis ofmyocardial ischemia. J Am Coll Cardiol 2009;54:1165–72.84. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, et al. Prevalence anddeterminants of troponin T elevation in the general population. Circulation 2006;113:1958–65.85. Eggers KM, Dellborg M, Oldgren J, Swahn E, Venge P, Lindahl B, et al. Risk prediction inchest pain patients by biochemical markers including estimates of renal function. Int J Cardiol2008;128:207–13.86. Mockel MD. Development of an optimized multimarker strategy for early risk assessment of patientswith acute coronary syndromes. Clin Chim Acta 2008;393:103–9.87. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM, Apple FS, et al. Multiple biomarker use fordetection of adverse events in patients presenting with symptoms suggestive of acute coronarysyndrome. Clin Chem 2007;53:874–81.88. Apple FS, Smith SW, Pearce LA, Schulz KM, Ler R, Murakami MAM, et al. Myeloperoxidase improvesrisk stratification in patients with ischemia and normal cardiac troponin I concentrations. Clin Chem2011;57:603–8.89. Bholasingh R, Cornel JH, Kamp O, Van Straalen JP, Sanders GT, Dijksman L, et al. The prognosticvalue of markers of inflammation in patients with troponin T-negative chest pain before dischargefrom the emergency department. Am J Med 2003;115:521–8.90. Blum AS. The prognostic value of high-sensitive C-reactive protein and cardiac troponin T in youngand middle-aged patients with chest pain without ECG changes. Eur J Intern Med 2003;14:310–14.91. Brennan ML, Penn MS, Van LF, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value ofmyeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595–604.92. Brown AM, Sease KL, Robey JL, Shofer FS, Hollander JE. The impact of B-type natriuretic peptide inaddition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergencydepartment chest pain patients with potential acute coronary syndrome. Ann Emerg Med2007;49:153–63.93. Brugger-Andersen TP. B-type natriuretic peptide is a long-term predictor of all-cause mortality,whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiacevents in chest pain patients: A prognostic study. BMC Cardiovasc Disord 2008;8:34.94. Cameron SJ, Sokoll LJ, Laterza OF, Shah S, Green GB, Cameron SJ, et al. A multi-marker approachfor the prediction of adverse events in patients with acute coronary syndromes. Clin Chim Acta2007;376:168–73.95. Consuegra-Sanchez LB-M. Ischemia-modified albumin predicts short-term outcome and 1-yearmortality in patients attending the emergency department for acute ischemic chest pain. HeartVessels 2008;23:174–80.96. De Winter RJ, Koster RW, Schotveld JH, Sturk A, Van Straalen JP, Sanders GT, et al. Prognostic valueof troponin T, myoglobin, and CK-MB mass in patients presenting with chest pain without acutemyocardial infarction. Heart 1996;75:235–9.97. Eggers KM, Kempf T, Allhoff T, Lindahl B, Wallentin L, Wollert KC, et al. Growth-differentiationfactor-15 for early risk stratification in patients with acute chest pain. Eur Heart J 2008;29:2327–35.98. Fromm R, Meyer D, Zimmerman J, Boudreaux A, Wun CC, Smalling R, et al. A double-blind,multicentered study comparing the accuracy of diagnostic markers to predict short- and long-termclinical events and their utility in patients presenting with chest pain. Clin Cardiol 2001;24:516–20.126NIHR Journals Library
DOI: 10.3310/hta17010 Health Technology Assessment 2013 Vol. 17 No. 199. Green GB, Skarbek-Borowski GW, Chan DW, Kelen GD, Green GB, Skarbek-Borowski GW, et al.Myoglobin for early risk stratification of emergency department patients with possible myocardialischemia. Acad Emerg Med 2000;7:625–36.100. Hillis GS, Taggart P, Hillis L, Zhao N, Dalsey WC, Mangione A, et al. Biochemical and clinicalpredictors of long-term outcome in patients with nonspecific chest pain and nondiagnosticelectrocardiograms. Am Heart J 200;145:88–94.101. Jaffery Z, Nowak R, Khoury N, Tokarski G, Lanfear DE, Jacobsen G, et al. Myoglobin and troponinI elevation predict 5-year mortality in patients with undifferentiated chest pain in the emergencydepartment. Am Heart J 2008;156:939–45.102. Jernberg T, Stridsberg M, Venge P, Lindahl B, Jernberg T, Stridsberg M, et al. N-terminal pro brainnatriuretic peptide on admission for early risk stratification of patients with chest pain and noST-segment elevation. J Am Coll Cardiol 2002;40:437–45.103. Kavsak PA, Wang XS, Henderson M, Ko DT, MacRae AR, Jaffe AS. PAPP-A as a marker of increasedlong-term risk in patients with chest pain. Clin Biochem 2009;42:1012–18.104. Kontos MC, Garg R, Anderson FP, Roberts CS, Ornato JP, Tatum JL, et al. Ability of myoglobin topredict mortality in patients admitted for exclusion of myocardial infarction. Am J Emerg Med2007;25:873–9.105. Laterza OF, Cameron SJ, Chappell D, Sokoll LJ, Green GB, Laterza OF, et al. Evaluation of pregnancyassociatedplasma protein A as a prognostic indicator in acute coronary syndrome patients. ClinChim Acta 2004;348:163–9.106. Lim J, Hawkins RC, Ng K, Chan SP, Cheng A, Ng KS, et al. A preliminary study of the utility ofcombined cardiac markers in the evaluation of patients presenting early with suspected acutecoronary syndrome. Ann Acad Med Singapore 2002;31:772–6.107. Lund J, Qin Q, Ilva T, Pettersson K, Voipio-Pulkki L, Porela P, et al. Circulating pregnancy-associatedplasma protein A predicts outcome in patients with acute coronary syndrome but no troponin Ielevation. Circulation 2003;108:1924–6.108. Manini AF, Ilgen J, Noble VE, Bamberg F, Koenig W, Bohan JS, et al. Derivation and validationof a sensitive IMA cutpoint to predict cardiac events in patients with chest pain. Emerg Med J2009;26:791–6.109. Markovic M, Ignjatovic S, Dajak M, Majkic-Singh N, Markovic M, Ignjatovic S, et al. Utilityof placental growth factor for prediction of 30-day adverse event in emergency departmentpopulation with non-ST elevation acute coronary syndrome. Clin Lab 2010;56:215–22.110. Mathew T, Menown I, Smith B, Smye M, Nesbitt S, Young I, et al. Diagnosis and risk stratification ofpatients with anginal pain and non-diagnostic electrocardiograms. QJM 1999;92:565–71.111. McCann CJ, Glover BM, Menown IB, Moore MJ, McEneny J, Owens CG, et al. Prognostic value ofa multimarker approach for patients presenting to hospital with acute chest pain. Am J Cardiol2009;103:22–8.112. McCord J, Nowak RM, Hudson MP, McCullough PA, Tomlanovich MC, Jacobsen G, et al. Theprognostic significance of serial myoglobin troponin I, and creatine kinase-MB measurements inpatients evaluated in the emergency department for acute coronary syndrome. Ann Emerg Med2003;42:343–50.113. Menown IB, Mathew TP, Gracey HM, Nesbitt GS, Murray P, Young IS, et al. Prediction of recurrentevents by D-Dimer and inflammatory markers in patients with normal cardiac troponin I (PREDICT).Study. Am Heart J 2003;145:986–92.© Queen’s Printer and Controller of HMSO 2013. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of Statefor Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journalsprovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should beaddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton SciencePark, Southampton SO16 7NS, UK.127
Page 1:
Health Technology AssessmentVOLUME
Page 7:
DOI: 10.3310/hta17010 Health Techno
Page 10 and 11:
ContentsAppendix 5 Expected discoun
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19:
Page 22 and 23:
BackgroundTABLE 1 Hospital admissio
Page 24 and 25:
Background2. investigation of the c
Page 26 and 27:
BackgroundComputed tomographic coro
Page 28 and 29:
Research questionsiii. the diagnost
Page 30 and 31:
Assessment of diagnostic and progno
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96: DOI: 10.3310/hta17010 Health Techno
Page 125: DOI: 10.3310/hta17010 Health Techno
Page 128 and 129: Discussionspecificity were 62% (95%
Page 130 and 131: Discussionneed for revascularisatio
Page 132 and 133: Discussionchanges in sensitivity an
Page 134 and 135: Discussionuncertainty about these p
Page 136 and 137: Discussiontroponin assays have bett
Page 138 and 139: ConclusionsSuggested research prior
Page 154 and 155: Appendix 144. heart-type fatty acid
Page 156 and 157: Appendix 1135. interleukin 33.mp. (
Page 158 and 159: Appendix 147. 37 and 45 (529)48. li
Page 164 and 165: Appendix 313. Fernandez Portales JG
Page 166 and 167: Appendix 346. Luscher MS, Ravkilde
Page 168 and 169: Appendix 316. Rao SV, Ohman EM, Gra
Page 198 and 199:
Appendix 9Clinical diagnosis of NST
Page 200 and 201:
Appendix 9respectively. Exercise EC
Page 202 and 203:
Appendix 93. Two reviewers will mak
Page 204 and 205:
Appendix 9The methodology used in t
Page 206 and 207:
Appendix 9ES (Information Resources
Page 208:
Appendix 923. Westwood ME, Whiting
show all

Systematic review, meta-analysis and economic modelling of ...

Create successful ePaper yourself

Delete template?

Save as template?